Niu, Lili https://orcid.org/0000-0003-4571-4368
Stinson, Sara Elizabeth https://orcid.org/0000-0002-1491-9179
Holm, Louise Aas https://orcid.org/0000-0002-5439-5429
Lund, Morten Asp Vonsild https://orcid.org/0000-0002-2711-1259
Fonvig, Cilius Esmann
Cobuccio, Leonardo
Meisner, Jonas
Juel, Helene Bæk
Fadista, Joao
Thiele, Maja
Krag, Aleksander
Holm, Jens-Christian https://orcid.org/0000-0003-4653-342X
Rasmussen, Simon https://orcid.org/0000-0001-6323-9041
Hansen, Torben https://orcid.org/0000-0001-8748-3831
Mann, Matthias https://orcid.org/0000-0003-1292-4799
Funding for this research was provided by:
Novo Nordisk Fonden (NNF15CC0001, NNF15OC0016692, NNF15CC0001, NNF15OC0016692, NNF15OC0016692, NNF15OC0016692, NNF20OC0059393, NNF18SA0034956, NNF21SA0072102, NNF21SA0072102, NNF15OC0016692, NNF20OC0059393, NNF15OC0016692, NNF15OC0016692, NNF14CC0001, NNF21SA0072102, NNF15OC0016544)
Region Sjælland (R32-A1191)
EC | Horizon 2020 Framework Programme (668031)
Article History
Received: 4 May 2023
Accepted: 13 January 2025
First Online: 19 February 2025
Competing interests
: M.M. is an indirect investor in Evosep. L.N. and J.F. are employees of Novo Nordisk; however, this work was conducted while L.N. was a full-time employee at the University of Copenhagen. M.T. is a co-founder and board member of Evido. She is also a board member of the non-governmental organization Alcohol & Society. She receives speaker fees from Siemens Healthcare, Echosens, Norgine, Madrigal, Takeda and Tillotts Pharma as well as advisory fees from Boehringer Ingelheim, Astra Zeneca, Novo Nordisk and GSK. A.K. is a co-founder and board member of Evido. He has served as a speaker for Novo Nordisk, Norgine and Siemens, and has participated in advisory boards for Siemens, Boehringer Ingelheim and Novo Nordisk. Additionally, he receives research support from Astra Zeneca, Siemens, Nordic Bioscience and Echosense, all outside the submitted work. The other authors declare no competing interests.